Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 312.90
-4.10 (-1.29%)
Aug 28, 2026, 4:59 PM CET
Zealand Pharma Financials Overview
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 4,644 | 9,215 | 62.69 | 342.79 | 103.99 | 108.55 |
Revenue Growth | -49.02% | 14598.86% | -81.71% | 229.65% | -4.20% | -43.47% |
Gross Profit Gross Profit Growth | 4,644 | 9,214 | 54.82 | 339.59 | 103.99 | 97.58 |
Operating Income Operating Income Growth | 2,307 | 6,917 | -1,269 | -561.24 | -816.6 | -782.14 |
Net Income Net Income Growth | 2,741 | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 |
Earnings Per Share EPS Growth | 38.53 | 90.22 | -16.24 | -12.44 | -26.02 | -23.75 |
EPS Growth | -58.86% | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Denmark Denmark Growth | 34.9 | 62.29 | 44.19 | 34.96 | - |
Switzerland Switzerland Growth | 9,180 | - | - | - | - |
United States United States Growth | - | 0.41 | 4.09 | 69.03 | 55.5 |
Total Total Growth | 9,215 | 62.69 | 342.79 | 103.99 | 108.5 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 14,457 | 15,109 | 9,046 | 1,633 | 1,178 | 1,428 |
Total Debt Total Debt Growth | 411 | 405.77 | 391.76 | 119.23 | 524.08 | 787.43 |
Net Cash (Debt) Net Cash Growth | 14,046 | 14,703 | 8,654 | 1,514 | 653.77 | 640.72 |
Net Cash Growth | -13.19% | 69.90% | 471.66% | 131.55% | 2.04% | -43.17% |
Net Cash Per Share Net Cash Per Share Growth | 197.47 | 205.50 | 130.26 | 26.75 | 14.15 | 14.95 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,753 | 6,532 | -930.82 | -425.67 | -942.31 | -1,212 |
Capital Expenditures CapEx Growth | -43.37 | -33.37 | -10.05 | -11.24 | -11.71 | -22.13 |
Free Cash Flow Free Cash Flow Growth | -1,796 | 6,499 | -940.87 | -436.91 | -954.02 | -1,234 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | 99.99% | 87.44% | 99.07% | 100.00% | 89.89% |
Operating Margin | 49.68% | 75.06% | -2024.33% | -163.73% | -785.30% | -720.57% |
Pretax Margin | 61.16% | 75.98% | -1728.23% | -206.79% | -934.78% | -699.14% |
Profit Margin | 59.02% | 70.05% | -1720.87% | -205.30% | -1156.05% | -937.99% |
FCF Margin | -38.68% | 70.52% | -1500.80% | -127.46% | -917.45% | -1136.94% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.12 | 5.09 | - | - | - | - |
Forward PE | - | 3.95 | 38.43 | 151.81 | 115.37 | 115.37 |
P/FCF Ratio | - | 5.06 | - | - | - | - |
PS Ratio | 4.59 | 3.57 | 806.30 | 63.55 | 99.69 | 57.77 |